RESEARCH PROFILE
TESAMORELIN
Growth Hormone Releasing Hormone Analog
Tesamorelin is a synthetic analog of human growth hormone releasing hormone that stimulates the pituitary GHRH receptor and increases endogenous growth hormone and downstream IGF-1 signaling.
It is FDA approved for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy.
FDA APPROVED FOR A SPECIFIC INDICATION • GHRH RECEPTOR AGONIST • HUMAN CLINICAL EVIDENCE
TESAMORELIN AT A GLANCE
Category
Growth hormone releasing hormone analog
Primary Target
GHRH receptor
Primary Research Pathway
Growth hormone • IGF-1 axis
Approved Indication
Reduction of excess abdominal fat in adults with HIV-associated lipodystrophy
Human Evidence
Large Phase III clinical program
Regulatory Status
FDA approved for a specific indication
IMPORTANT DISTINCTION
Tesamorelin's FDA approval is indication specific.
Its approved use concerns excess abdominal fat associated with HIV lipodystrophy.
That approval should not be interpreted as FDA approval for:
General weight loss
Obesity treatment
Bodybuilding
Muscle gain
Anti-aging
General visceral-fat reduction in otherwise healthy individuals
Off-label use and FDA-approved use are not the same thing.
WHAT IS TESAMORELIN?
Tesamorelin is a synthetic analog of growth hormone releasing hormone, or GHRH.
It is based on the natural human GHRH sequence but incorporates a structural modification intended to improve stability while preserving biological activity at the GHRH receptor.
Tesamorelin acts upstream of growth hormone.
Rather than providing exogenous GH directly, it stimulates the pituitary gland to release the body's own growth hormone.
This endogenous GH release subsequently increases signaling through the GH/IGF-1 axis.
Tesamorelin has been studied extensively in people with HIV-associated lipodystrophy, particularly for its effects on visceral adipose tissue, the metabolically active fat located around internal abdominal organs.
Its clinical development and FDA approval distinguish it from many other compounds commonly discussed in peptide research.
MECHANISM OF ACTION
Tesamorelin acts through the physiological growth hormone releasing hormone pathway.
GHRH RECEPTOR
Tesamorelin binds to GHRH receptors on pituitary somatotroph cells.
This activates intracellular signaling pathways involved in growth hormone synthesis and release.
ENDOGENOUS GH RELEASE
Tesamorelin promotes secretion of endogenous growth hormone rather than supplying recombinant GH directly.
The resulting GH response remains influenced by physiological feedback systems within the hypothalamic-pituitary axis.
IGF-1 SIGNALING
Growth hormone released from the pituitary stimulates production of insulin-like growth factor 1, or IGF-1.
IGF-1 is an important downstream mediator of many GH-axis effects and is routinely relevant to Tesamorelin monitoring.
VISCERAL FAT
Clinical research demonstrated that Tesamorelin can reduce visceral adipose tissue, or VAT, in the population for which it was studied and approved.
Visceral fat differs from subcutaneous fat located directly under the skin.
The strongest evidence for Tesamorelin therefore concerns changes in abdominal visceral fat in adults with HIV-associated lipodystrophy, not generalized weight loss.
PHYSIOLOGICAL GH AXIS
Because Tesamorelin stimulates endogenous GH release, rather than continuously providing exogenous growth hormone, its pharmacology retains more of the body's normal feedback regulation than direct GH administration.
WHAT THE RESEARCH SHOWS
PHASE III HIV LIPODYSTROPHY EVIDENCE
Tesamorelin has one of the stronger human clinical evidence bases among peptide-based GH-axis therapies.
Two large Phase III trials evaluated Tesamorelin in adults with HIV-associated lipodystrophy and excess abdominal fat.
Your Project profile summarizes one trial as showing approximately 15.2% reduction in visceral adipose tissue at 26 weeks compared with placebo.
A second Phase III trial reported approximately 11.7% reduction in visceral adipose tissue at 26 weeks.
These findings contributed to FDA approval.
POOLED PHASE III EVIDENCE
Pooled analyses across the Phase III program included more than 800 participants.
The combined evidence showed consistent reductions in visceral abdominal fat during treatment.
Your Project source also notes that these effects tended to move back toward baseline after treatment was discontinued.
This is important because it suggests the effect is related to ongoing therapy rather than a permanent remodeling of adipose tissue.
LIVER FAT RESEARCH
Tesamorelin has also been studied in adults with HIV and nonalcoholic fatty liver disease.
A randomized clinical trial reported approximately 32% relative reduction in liver fat compared with placebo over 12 months.
The study also reported lower progression of fibrosis compared with placebo.
These findings are clinically interesting but should not be confused with the FDA-approved indication.
Tesamorelin is not FDA approved specifically as a treatment for NAFLD or liver fibrosis.
BODY COMPOSITION
Clinical trials generally showed reductions in visceral fat without the same degree of generalized body-weight loss seen with modern incretin-based therapies.
That distinction matters.
Tesamorelin should not be described as a conventional weight-loss drug.
LONGER TERM EFFECTS
Your Project profile notes that visceral-fat reductions were maintained during continued therapy in extension studies.
After treatment stopped, visceral adipose tissue tended to increase again toward baseline.
IMPORTANT EVIDENCE LIMITATIONS
The strongest direct evidence concerns:
Adults with HIV-associated lipodystrophy
Excess abdominal visceral fat
Defined clinical-trial dosing and pharmaceutical formulations
Evidence from these populations should not automatically be generalized to healthy adults, athletes, bodybuilding populations, or people seeking cosmetic fat loss.
SAFETY & RESEARCH CONSIDERATIONS
Tesamorelin has substantial human safety data from controlled clinical trials and FDA-approved use, but its labeling includes important contraindications and monitoring considerations.
COMMONLY REPORTED EFFECTS
Your Project profile identifies injection-site reactions as among the most common adverse effects.
These may include:
Redness
Itching
Pain
Swelling
Rash
Other commonly reported effects include:
Fluid retention
Joint pain
Muscle aches
GLUCOSE CHANGES
Tesamorelin can affect glucose metabolism.
Clinical trials reported a higher proportion of participants developing elevated HbA1c compared with placebo.
Monitoring of glucose status is therefore relevant during therapy.
IGF-1 ELEVATION
Tesamorelin increases IGF-1.
Persistent elevation of IGF-1 can require clinical review, particularly when values rise substantially above the age-adjusted reference range.
ANTIBODY DEVELOPMENT
Your Project source reports that approximately half of trial participants developed anti-Tesamorelin IgG antibodies after 26 to 52 weeks of treatment.
The available trial data did not clearly show that antibody formation eliminated the visceral-fat or IGF-1 response.
FLUID RETENTION
Because Tesamorelin increases GH-axis activity, fluid retention-related effects can occur.
These may include swelling, joint discomfort, or neurologic symptoms such as numbness or tingling.
CONTRAINDICATIONS
Your Project profile identifies major contraindications including:
Active malignancy
Pregnancy
Known hypersensitivity
Major disruption of the hypothalamic-pituitary axis
Tesamorelin should also be used cautiously in people with significant glucose intolerance or diabetes.
CANCER & IGF-1 CONSIDERATIONS
GH and IGF-1 participate in cellular growth pathways.
For this reason, active malignancy is an important contraindication, and cancer history may require individualized clinical review.
REGULATORY CONTEXT
TESAMORELIN IS FDA APPROVED
Tesamorelin is an FDA-approved prescription drug ingredient.
Its approved indication is:
Reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy
Your Project source identifies the original branded product as Egrifta, with later formulations including Egrifta SV and Egrifta WR.
INDICATION SPECIFIC APPROVAL
FDA approval applies to:
The approved Tesamorelin drug product
Its approved formulation
Its labeling
Its manufacturing controls
Its specific patient population
Its approved indication
That approval should not be extended to unrelated research-grade Tesamorelin preparations.
OFF LABEL USE
Use of Tesamorelin for purposes outside HIV-associated lipodystrophy is considered off-label.
Examples include use for:
General fat loss
Bodybuilding
Anti-aging
Healthy-person visceral-fat reduction
Performance enhancement
Those uses do not carry the same regulatory status as the FDA-approved indication.
NOT A CONTROLLED SUBSTANCE
Your Project profile states that Tesamorelin is not scheduled under the U.S. Controlled Substances Act.
It is nevertheless a prescription medication when used as the FDA-approved drug.
ANTI-DOPING STATUS
Tesamorelin is prohibited under World Anti-Doping Agency rules as a peptide hormone/growth hormone releasing factor.
Competitive athletes should not assume that FDA approval makes it permissible under anti-doping rules.
RESEARCH PRODUCT DISTINCTION
A research-grade Tesamorelin vial should not be represented as equivalent to an FDA-approved pharmaceutical product merely because both contain Tesamorelin.
Manufacturing controls, formulation, sterility assurance, labeling, quality systems, and regulatory oversight may differ substantially.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation for specific samples and lots represented in its research library.
TESAMORELIN 10 MG
Laboratory
Optiq Health Labs
Lot
ld08282026-1
Sample ID
1270.OPT.260910
Report Date
September 18, 2026
Sample Matrix
Lyophilized Peptide
Intended Use
Research Use Only
Reported Net Content
10.27 mg/vial
Reported Purity
99.3%
Identity
LC-MS confirmation • Tesamorelin tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth
The Project COA packet identifies this specific Tesamorelin 10 mg sample and lot as tested by Optiq Health Labs. The report applies only to the submitted sample and does not establish the characteristics of unrelated vials, batches, or products.
IMPORTANT COA LIMITATION
Analytical results apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
Croix's documentation standard requires matching the product, strength, lot or batch, sample ID, laboratory, and report date before analytical documentation is presented as supporting a product.
A passing COA also does not establish FDA approval, clinical efficacy, or equivalence to the FDA-approved Egrifta formulations.
SELECTED RESEARCH & REFERENCES
Falutz J, et al.
Effects of Tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat.
Phase III clinical research evaluating visceral adipose tissue reduction in HIV-associated lipodystrophy.
Falutz J, et al.
Pooled analysis of multicenter Phase III Tesamorelin trials.
Human clinical evidence supporting reduction of visceral abdominal fat and safety outcomes.
Stanley TL, Fourman LT, Feldpausch MN, et al.
Effects of Tesamorelin on non-alcoholic fatty liver disease in HIV: a randomized, double-blind, multicentre trial.
Lancet HIV. 2019.
Randomized human research examining liver-fat reduction and related outcomes.
Fourman LT, Stanley TL, et al.
Research examining hepatic transcriptional signatures in HIV-associated NAFLD during Tesamorelin treatment.
Grinspoon S, et al.
Research examining growth hormone releasing hormone analog effects on endogenous GH pulsatility and insulin sensitivity.
U.S. Food & Drug Administration
Egrifta SV prescribing information.
U.S. Food & Drug Administration
Egrifta WR prescribing information.
EVIDENCE NOTE
Tesamorelin has substantial human clinical evidence and a genuine FDA-approved indication.
However, the strongest evidence is specific to HIV-associated lipodystrophy and defined clinical populations.
Evidence supporting that indication should not be generalized to cosmetic fat loss, bodybuilding, anti-aging, or otherwise healthy individuals.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice.
Tesamorelin is an FDA-approved active pharmaceutical ingredient for a specific indication involving excess abdominal fat in adults with HIV-associated lipodystrophy.
That approval should not be interpreted as establishing unrelated Tesamorelin research products as FDA approved or as validating use for general weight loss, bodybuilding, anti-aging, athletic performance, or cosmetic body composition.
Clinical evidence, safety information, and regulatory status depend on the formulation, population, indication, and product being discussed.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.